Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia.

abstract：:A 4(3/4)-year-old male with Down syndrome (DS) presented with unsteady gait and fatigue. Neuroimaging revealed a cerebellar mass with concomitant obstructive hydrocephalus and additional metastatic lesions. He was successfully treated and is still in complete remission 5 years from diagnosis. The present case illustra...

journal_title：Pediatric blood & cancer

authors： Benesch M,Moser A,Sovinz P,Lackner H,Schwinger W,Eder H,Urban C

更新日期：2009-12-01 00:00:00

abstract：BACKGROUND:A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors. PROCEDURE:Oral vorinostat was administered on days 1-5 and 8-12 of a 21-day cycle (starting dose 180 mg/m(2...

journal_title：Pediatric blood & cancer

authors： Muscal JA,Thompson PA,Horton TM,Ingle AM,Ahern CH,McGovern RM,Reid JM,Ames MM,Espinoza-Delgado I,Weigel BJ,Blaney SM

更新日期：2013-03-01 00:00:00

abstract：BACKGROUND:Histology after intensive induction chemotherapy is expected to become a beacon indicating when and how extensively radical surgery and lymph node dissection should be performed in advanced neuroblastoma. A thorough histologic review of surgical specimens was undertaken. PROCEDURE:All specimens from 34 pati...

journal_title：Pediatric blood & cancer

authors： Tsuchida Y,Miyauchi J,Kuroiwa M,Suzuki N,Sakamoto J,Suzuki M,Shitara T

更新日期：2005-10-15 00:00:00

abstract：BACKGROUND:Alvespimycin (17-DMAG, KOS-1022), a potent small-molecule inhibitor of the protein chaperone Hsp90, is being developed as an anticancer agent because of the multiple Hsp90 client proteins involved in cancer cell growth and survival. PROCEDURES:Alvespimycin was tested against the in vitro panel of the Pediat...

journal_title：Pediatric blood & cancer

authors： Smith MA,Morton CL,Phelps DA,Kolb EA,Lock R,Carol H,Reynolds CP,Maris JM,Keir ST,Wu J,Houghton PJ

更新日期：2008-07-01 00:00:00

abstract：PURPOSE:To assess health and musculoskeletal function in survivors of pediatric sarcomas. PATIENTS AND METHODS:Thirty-two individuals treated for Ewing sarcoma family of tumors (ESFT), rhabdomyosarcoma (RMS), or non-rhabdomyosarcoma soft tissue sarcomas (NR-STS) with multi-modality therapy were enrolled on this cross-...

journal_title：Pediatric blood & cancer

authors： Mansky P,Arai A,Stratton P,Bernstein D,Long L,Reynolds J,Chen D,Steinberg SM,Lavende N,Hoffman K,Nathan PC,Parks R,Augustine E,Chaudhry U,Derdak J,Wiener L,Gerber L,Mackall C

更新日期：2007-02-01 00:00:00

abstract：:We describe here the outcomes of reduced-toxicity alternate-donor stem cell transplant (SCT) with posttransplant cyclophosphamide (PTCy) for primary immunodeficiency disorders (PIDs) in eight children (haploidentical-seven and matched unrelated donor-one). The conditioning was with serotherapy (alemtuzumab-3/rabbit-an...

journal_title：Pediatric blood & cancer

authors： Rastogi N,Katewa S,Thakkar D,Kohli S,Nivargi S,Yadav SP

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Physical fitness is an important determinant of quality of life (QOL) after hematopoietic stem cell transplantation. Cardiac function can influence exercise performance. The aim of this study was to assess these factors and their interrelationship. PROCEDURE:Children underwent cardiopulmonary exercise testi...

journal_title：Pediatric blood & cancer

authors： Vandekerckhove K,De Waele K,Minne A,Coomans I,De Groote K,Panzer J,Dhooge C,Bordon V,De Wolf D,Boone J

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Fever and neutropenia (F&N) is a pediatric oncology emergency due to the risk of disseminated infection. Quality improvement (QI) efforts to improve time to antibiotics for F&N in the emergency department have been documented, but the issue has not been studied in the established inpatient setting. PROCEDUR...

journal_title：Pediatric blood & cancer

authors： Green AL,Yi J,Bezler N,Pikman Y,Tubman VN,Obeng EA,O'Neil T,Mersereau R,Morrissey L,Billett AL

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:A desperate need for novel therapies in pediatric ependymoma (EPN) exists, as chemotherapy remains ineffective and radiotherapy often fails. EPN have significant infiltration of immune cells, which correlates with outcome. Immune checkpoint inhibitors provide an avenue for new treatments. This study characte...

journal_title：Pediatric blood & cancer

authors： Witt DA,Donson AM,Amani V,Moreira DC,Sanford B,Hoffman LM,Handler MH,Levy JMM,Jones KL,Nellan A,Foreman NK,Griesinger AM

更新日期：2018-05-01 00:00:00

abstract：:Poverty is an important patient-reported outcome of therapy and a potential predictor of outcome disparities in pediatric cancer. We previously identified that nearly 30% of pediatric cancer families experience household material hardship (HMH), a concrete measure of poverty including food, energy, or housing insecuri...

journal_title：Pediatric blood & cancer

authors： Bilodeau M,Ma C,Al-Sayegh H,Wolfe J,Bona K

更新日期：2018-01-01 00:00:00

abstract：:We present three pediatric patients with BRAFV600E mutant high-grade gliomas treated by vemurafenib on a nominative authorization level at our institution. One patient with anaplastic ganglioglioma experienced confirmed partial tumor response and significant clinical improvement and she is alive 20 months after start ...

journal_title：Pediatric blood & cancer

authors： Bautista F,Paci A,Minard-Colin V,Dufour C,Grill J,Lacroix L,Varlet P,Valteau-Couanet D,Geoerger B

更新日期：2014-06-01 00:00:00

abstract：:Risk-adapted, response-based therapies for pediatric Hodgkin lymphoma have resulted in 5-year survival exceeding 90%. Although high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of childr...

journal_title：Pediatric blood & cancer

authors： Harker-Murray PD,Drachtman RA,Hodgson DC,Chauvenet AR,Kelly KM,Cole PD

更新日期：2014-04-01 00:00:00

abstract：BACKGROUND:Posterior fossa syndrome (PFS) is defined as the temporary and complete loss of speech after posterior fossa surgery. The goal of this study was to identify incidence and risk factors for PFS and to determine accompanying neurobehavioral and psychologic problems. PROCEDURE:Between May 2007 and April 2009, c...

journal_title：Pediatric blood & cancer

authors： Küpeli S,Yalçın B,Bilginer B,Akalan N,Haksal P,Büyükpamukçu M

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms have been implicated in childhood acute lymphoblastic leukemia (ALL) risk, but previously published studies were inconsistent and recent meta-analyses were not adequate. PROCEDURES:In a meta-analysis of 21 publications with 4,706 cas...

journal_title：Pediatric blood & cancer

authors： Yan J,Yin M,Dreyer ZE,Scheurer ME,Kamdar K,Wei Q,Okcu MF

更新日期：2012-04-01 00:00:00

abstract：BACKGROUND:Although intra-retinal tumor has long been staged presurgically according to the Reese-Ellsworth (R-E) system, retinoblastoma differs from other pediatric neoplasms in never having had a widely accepted classification system that encompasses the entire spectrum of the disease. Comparisons among studies that ...

journal_title：Pediatric blood & cancer

authors： Chantada G,Doz F,Antoneli CB,Grundy R,Clare Stannard FF,Dunkel IJ,Grabowski E,Leal-Leal C,Rodríguez-Galindo C,Schvartzman E,Popovic MB,Kremens B,Meadows AT,Zucker JM

更新日期：2006-11-01 00:00:00

abstract：:To assess safety and tolerability, we administered valacyclovir, an oral anti-viral medication that inhibits erythrocyte sickling in vitro, to 14 subjects with sickle-cell anemia for 1 week at a standard dose of 1,000 mg every 8 hr. No clinically significant adverse effects occurred. In 11 subjects in steady state, th...

journal_title：Pediatric blood & cancer

authors： Ender KL,DeBellis RH,Erlanger BF,Billote GB,Brittenham GM

更新日期：2011-05-01 00:00:00

abstract：:Undifferentiated embryonal sarcoma of the liver (UESL) is a rare aggressive mesenchymal pediatric tumor. Previously, reported outcomes have been very poor. Here, we report a single-center experience of five patients with UESL treated with upfront gross total resection and adjuvant chemotherapy. We have a median follow...

journal_title：Pediatric blood & cancer

authors： Mathias MD,Ambati SR,Chou AJ,Slotkin EK,Wexler LH,Meyers PA,Magnan H

更新日期：2016-12-01 00:00:00

abstract：OBJECTIVES:The aim of this study was to assess glomerular and tubular renal function after HSCT in children in a prospective trial. METHODS:Renal function was assessed prospectively before HSCT (on day -10), on days +30, +100, and at least 6 months after transplantation in 34 patients (21 females/13 males) with a mean...

journal_title：Pediatric blood & cancer

authors： Hazar V,Gungor O,Guven AG,Aydin F,Akbas H,Gungor F,Tezcan G,Akman S,Yesilipek A

更新日期：2009-08-01 00:00:00

abstract：BACKGROUND:Insomnia is common among adolescent and young adult (AYA) cancer survivors. Cognitive-behavioral therapy for insomnia (CBT-I) is considered the gold standard treatment. Standard CBT-I was designed for adults and not adapted to the unique medical, psychosocial, and developmental needs of AYA cancer survivors,...

journal_title：Pediatric blood & cancer

authors： Zhou ES,Recklitis CJ

更新日期：2020-09-01 00:00:00

abstract：:Peripheral neuropathy is a well-known side effect of vincristine, a micro-tubule inhibitor commonly used to treat malignancies. Severe neurologic adverse events can occur in patients with Charcot-Marie-Tooth disease (CMT) treated with vincristine. Voriconazole is an antifungal agent used increasingly in children with ...

journal_title：Pediatric blood & cancer

authors： Porter CC,Carver AE,Albano EA

更新日期：2009-02-01 00:00:00

abstract：BACKGROUND:Despite advances in therapy, outcome in many high-grade pediatric central nervous system (CNS) tumors remains poor. The focus of neuro-oncology research has thus turned towards identifying novel therapeutic targets. Poly(ADP-ribose) polymerase-1 (PARP1) is a DNA repair protein that has been studied in a vari...

journal_title：Pediatric blood & cancer

authors： Barton VN,Donson AM,Kleinschmidt-DeMasters BK,Gore L,Liu AK,Foreman NK

更新日期：2009-12-15 00:00:00

abstract：BACKGROUND:Hepatic veno-occlusive disease (VOD) is one of the most serious complications in stem cell transplantation (SCT). Although plasma protein C activity decreases in VOD after SCT, the timeframe of plasma protein C activity decreases during SCT is not known. PROCEDURE:We examined levels of plasma protein C seri...

journal_title：Pediatric blood & cancer

authors： Iguchi A,Kobayashi R,Kaneda M,Kobayashi K

更新日期：2010-03-01 00:00:00

abstract：BACKGROUND:Survival of osteosarcoma patients has reached a plateau with the addition of chemotherapy and in part predicted based on histologic response. Risk-adapted therapy might be an alternative approach. We aimed to identify risk groups using clinical variables available at time of diagnosis in order to better pred...

journal_title：Pediatric blood & cancer

authors： Lee JA,Kim MS,Kim DH,Lim JS,Park KD,Song WS,Cho WH,Lee SY,Jeon DG

更新日期：2009-03-01 00:00:00

abstract：BACKGROUND:Systematic assessment of emotional distress is recommended in after care. Yet, it is unclear if parent report may be used as a proxy of child report. The aim of this study was to assess agreements and differences and explore possible moderators of disagreement between child and parent ratings. METHODS:Sixty...

journal_title：Pediatric blood & cancer

authors： Abate C,Lippé S,Bertout L,Drouin S,Krajinovic M,Rondeau É,Sinnett D,Laverdière C,Sultan S

更新日期：2018-02-01 00:00:00

abstract：INTRODUCTION:Our objectives were to design and validate methods to identify relapse and hematopoietic stem cell transplantation (HSCT) in children with acute lymphoblastic leukemia (ALL) using administrative data representing hospitalizations at US pediatric institutions. METHODS:We developed daily billing and ICD-9 c...

journal_title：Pediatric blood & cancer

authors： Cahen VC,Li Y,Getz KD,Elgarten CW,DiNofia AM,Wilkes JJ,Winestone LE,Huang YV,Miller TP,Gramatges MM,Rabin KR,Fisher BT,Aplenc R,Seif AE

更新日期：2020-05-11 00:00:00

abstract：:A major hallmark of NF1 is the development of benign tumors, including peripheral neurofibromas, plexiform neurofibromas, gliomas of the optic tract, other low grade gliomas, and pheochromocytomas. Hepatoblastoma have not been previously reported in patients with neurofibromatosis type 1. We present a case of a 9-mont...

journal_title：Pediatric blood & cancer

authors： Uçar C,Calişkan U,Toy H,Günel E

更新日期：2007-09-01 00:00:00

abstract：:Chronic granulomatous disease (CGD) is an immune deficiency characterized by defective neutrophil function and increased risk of life-threatening infections. Allogeneic hematopoietic cell transplantation is curative for CGD, and conditioning regimen impacts transplant-related outcomes. We report a single-center prospe...

journal_title：Pediatric blood & cancer

authors： Bhatt ST,Schulz G,Hente M,Slater A,Murray L,Shenoy S,Bednarski JJ

更新日期：2020-01-01 00:00:00

abstract：PURPOSE:This pilot study was done to determine the feasibility and accuracy of University of Florida/National Cancer Institute (UF/NCI) phantoms and Monte Carlo (MC) retrospective dosimetry and had two aims: (1) to determine the anatomic accuracy of UF/NCI phantoms by comparing 3D organ doses in National Wilms Tumor St...

journal_title：Pediatric blood & cancer

authors： Kalapurakal JA,Gopalakrishnan M,Mille M,Helenowski I,Peterson S,Rigsby C,Laurie F,Jung JW,Fitzgerald TJ,Lee C

更新日期：2018-12-01 00:00:00

abstract：:This is the case report of a 14-year young female who was diagnosed with solitary bone plasmacytoma (SBP) of proximal tibia and was treated by local involved field radiotherapy. We present the clinical, radiological and pathological findings of the case and review of the available treatment options and prognosis of th...

journal_title：Pediatric blood & cancer

authors： Kumar P,Sharma SC,Saikia UN,Kumar N,Vyas S,Angurana SL

更新日期：2011-01-01 00:00:00

abstract：:Immunotherapy with the anti-GD2 monoclonal antibody ch14.18, or dinutuximab, represents an important therapeutic advance in the treatment of pediatric high-risk neuroblastoma and is now considered part of standard of care in this patient population. To date, transverse myelitis as a result of dinutuximab therapy has n...

journal_title：Pediatric blood & cancer

authors： Ding YY,Panzer J,Maris JM,Castañeda A,Gomez-Chiari M,Mora J

更新日期：2018-01-01 00:00:00